Intel stock spikes after report of possible US government stake
SAN DIEGO - Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company with a market capitalization of $580.66 million, announced Monday plans to commence an underwritten public offering of $250 million of common stock shares, subject to market conditions. The stock is trading near its 52-week high at $44.88, according to InvestingPro data.
The biotechnology company, which develops drug-Fc conjugate therapeutics through its Cloudbreak platform, intends to grant underwriters a 30-day option to purchase up to an additional 15% of shares sold in the offering. While InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 3.87, it faces challenges with rapid cash burn and weak profit margins.
J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor are serving as joint book-running managers for the proposed offering.
The offering will be made pursuant to a shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on May 8, 2025, which became effective on May 15, 2025.
Cidara’s lead drug candidate, CD388, is a long-acting antiviral designed for universal prevention of seasonal and pandemic influenza with a single dose. The company received Fast Track Designation from the FDA for CD388 in June 2023 and completed enrollment of its Phase 2b NAVIGATE trial in December 2024.
The company also develops oncology treatments, with investigational new drug application clearance received in July 2024 for CBO421, targeting CD73 in solid tumors.
The announcement noted that there is no assurance regarding the completion, timing, or actual terms of the proposed offering. The information is based on a company press release statement.
In other recent news, Cidara Therapeutics has reported promising results from its Phase 2b NAVIGATE trial for its investigational influenza prevention treatment, CD388. The trial met its primary and all secondary efficacy endpoints, demonstrating significant prevention efficacy across all tested doses. The highest dose showed a 76% efficacy against influenza over 24 weeks, with the drug maintaining protection up to 28 weeks without safety concerns. Following these results, Cidara has requested an end of Phase 2 meeting with the FDA to discuss the design of a Phase 3 trial.
Analyst firms have responded positively to these developments. H.C. Wainwright has assumed coverage with a buy rating, highlighting the novel approach of CD388 in providing universal protection against influenza. Citizens JMP reaffirmed its Market Outperform rating with a price target of $47, citing the potential advantages of CD388 over existing flu vaccines. Needham raised its price target to $36, maintaining a Buy rating, and expressed optimism about the trial’s outcome based on earlier data. These recent developments underscore the growing confidence in Cidara’s potential to address unmet medical needs in influenza prevention.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.